Cargando…

PD-L1 Expression in Triple-negative Breast Cancer—a Comparative Study of 3 Different Antibodies

Assessment of programmed death protein-ligand 1 (PD-L1) in triple-negative breast cancer (TNBC) has entered daily practice to identify patients eligible for treatment with immune checkpoint inhibitors. However, different antibodies and different cut-offs for PD-L1 positivity are used, and the interc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlajnic, Tatjana, Baur, Fabienne, Soysal, Savas D., Weber, Walter P., Piscuoglio, Salvatore, Muenst, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983741/ https://www.ncbi.nlm.nih.gov/pubmed/36165931 http://dx.doi.org/10.1097/PAI.0000000000001062

Ejemplares similares

Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer
por: Zeindler, Jasmin, et al.
Publicado: (2019)

An Integrated Epigenomic and Genomic View on Phyllodes and Phyllodes-like Breast Tumors
por: Hench, Juergen, et al.
Publicado: (2022)

Pregnancy at early age is associated with a reduction of progesterone-responsive cells and epithelial Wnt signaling in human breast tissue
por: Muenst, Simone, et al.
Publicado: (2017)

Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients
por: Soysal, Savas D., et al.
Publicado: (2019)

Cylindroma of the breast with CYLD gene mutation: a case report and review of the literature
por: Escher-Michlig, Vanessa, et al.
Publicado: (2023)

Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer
por: Mechera, Robert, et al.
Publicado: (2019)

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
por: Sun, Woo Young, et al.
Publicado: (2016)

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
por: Tashireva, Liubov A., et al.
Publicado: (2023)

PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
por: Alkaabi, Duaa, et al.
Publicado: (2023)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Nuclear Expression of Snail Is an Independent Negative Prognostic Factor in Human Breast Cancer
por: Muenst, S., et al.
Publicado: (2013)

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
por: Schmidt, Gilda, et al.
Publicado: (2022)

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers
por: Barrett, Michael T., et al.
Publicado: (2018)

Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
por: Chen, Xingyu, et al.
Publicado: (2022)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer
por: Wang, Chaoyang
Publicado: (2022)

Natural Blockers of PD-1/PD-L1 Interaction for the Immunotherapy of Triple-Negative Breast Cancer-Brain Metastasis
por: Nakhjavani, Maryam, et al.
Publicado: (2022)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer
por: Ren, Yifan, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
por: Mathias, Carolina, et al.
Publicado: (2023)

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
por: Reguera-Nuñez, Elaine, et al.
Publicado: (2019)

The short- and long-term outcome after the surgical management of common bile duct stones in a tertiary referral hospital
por: Hess, Gabriel F., et al.
Publicado: (2023)

Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
por: Tang, Yuxia, et al.
Publicado: (2022)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer
por: Chen, Chunhua, et al.
Publicado: (2021)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

MCT4/Lactate Promotes PD-L1 Glycosylation in Triple-Negative Breast Cancer Cells
por: Duan, Xianxian, et al.
Publicado: (2022)

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
por: Cheung, Anthony, et al.
Publicado: (2022)

Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer
por: Qiu, Yufan, et al.
Publicado: (2021)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022)

Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials
por: Elmakaty, Ibrahim, et al.
Publicado: (2023)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

A high-throughput drug screen reveals means to differentiate triple-negative breast cancer
por: Vulin, Milica, et al.
Publicado: (2022)

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o6a6h3hnudgo2dtagascckm8l9